Abstract: The present disclosure relates to a quinoline derivative which inhibits the activity of histone methyltransferases (ESET/SETDB1) specific for the histone molecule H3K9 or a pharmaceutically acceptable salt thereof and a use thereof.

Abstract: The present disclosure relates to a pre-5th-Generation (5G) or 5G communication system to be provided for supporting higher data rates Beyond 4th-Generation (4G) communication system such as Long Term Evolution (LTE). A subscriber server supporting subscription of an electronic device in a communication system is provided. The subscriber server includes a transceiver configured to transmit and receive a signal, and a controller configured to receive a first subscription connection request message of the electronic device from a terminal, the first subscription connection request message including subscription terminal information of the terminal and identification information of the electronic device, authenticate a user of the terminal on a basis of the subscription terminal information included in the received first subscription connection request message, and transmit a second subscription connection request message of the electronic device to a support server if the user authentication has succeeded.

Abstract: The present invention provides a carbazole derivative represented by Formula 1: wherein X is CH2 or C(O), Y is selected from NR1R2, piperidinyl groups in which two of the carbon atoms are substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups, n is an integer from 2 to 5, R1 and R2, which may be identical or different, are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 may be bonded together to form a ring, R3 and R4, which may be identical or different, are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to a pre-5th-Generation (5G) or 5G communication system to be provided for supporting higher data rates Beyond 4th-Generation (4G) communication system such as Long Term Evolution (LTE). A subscriber server supporting subscription of an electronic device in a communication system is provided. The subscriber server includes a transceiver configured to transmit and receive a signal, and a controller configured to receive a first subscription connection request message of the electronic device from a terminal, the first subscription connection request message including subscription terminal information of the terminal and identification information of the electronic device, authenticate a user of the terminal on a basis of the subscription terminal information included in the received first subscription connection request message, and transmit a second subscription connection request message of the electronic device to a support server if the user authentication has succeeded.

Abstract: A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

Abstract: A mobile terminal including a communication unit configured to communicate with at least one external terminal; a memory configured to store at least a first and second operating system including at least first and second modes, respectively; and a controller configured to execute the first operating system and to activate the first mode corresponding to the first operating system, to display a first information screen corresponding to the activated first mode on a display of the mobile terminal, to receive an event signal indicating an event related to the second mode has occurred on the mobile terminal, and to selectively display event information related to the event of the second mode on a display of the at least one external terminal.

Abstract: Disclosed are carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT7 receptor. The carbazole derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for the 5-HT7 serotonin receptor and antagonistic activities against the 5-HT7 serotonin receptor. Further disclosed are pharmaceutical compositions including the compounds as active ingredients. The pharmaceutical compositions are useful as therapeutic and prophylactic agents for central nervous system diseases where antagonistic activities against 5-HT7 are required, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.

Abstract: A mobile terminal including a communication unit configured to communicate with at least one external terminal; a memory configured to store at least first and second operating systems including at least first and second modes, respectively; and a controller configured to activate the first mode using the first operating system, to display, in a first display region of a display unit of the mobile terminal, the activated first mode, and to display in a second display region of the display unit, at least one second indicator that when selected, activates a second corresponding application in the second mode.

Abstract: A power storage method for an energy storage system (ESS) is provided. The method includes determining a total quantity of power currently available in a power supply and a quantity of power currently required by a plurality of loads, determining a quantity of residual power currently available based on the total quantity of power currently available and the quantity of power currently required, and charging an ESS of a load determined as having a highest priority with the total power currently available while charging other ESSs of other loads with the residual power currently available.

Abstract: A method of controlling charging/discharging of battery packs in an energy storage system (ESS) includes designating first battery packs, managed by a first battery management system (BMS), as a charging group and designating second battery packs, managed by a second BMS, as a discharging group. The method further includes controlling the first BMS to permit only the first battery packs designated as the charging group to undergo a charging operation when the ESS is operated in a charging mode, and controlling the second BMS to permit only the second battery packs designated as the discharging group to undergo a discharging operation when the ESS is operated in a discharging mode.

Abstract: An electric power management method of an electric power management device includes controlling a first power generator to operate according to a preset operating plan, calculating an available amount of stored power by subtracting a required amount of emergency power from an amount of electric power stored in an energy storage system when a power generation amount of the first power generator is less than an electric power use amount of a plurality of electric power use devices, controlling a second power to operate when a sum of the power generation amount of the first power generator and the amount of electrical power stored in the energy management system is less than the electric power use amount, and interrupting electric power of the electric power use devices in ascending order of priority.

Abstract: The present invention relates to a camera module mounted with an external look-forming holder improved in heat emission function, the camera module including: a housing; a lens insertion hole opened toward an upper surface of the housing for insertion of a lens; a filter attachment unit formed on a floor surface of the housing for attaching a filter; and a heat emission outlet formed on an upper surface of the lens insertion hole in an upper-wide/bottom-narrow shape, wherein a heat emission outlet is formed at an upper surface of a lens insertion hole to induce heat generated from inside of a housing to be emitted to outside along an inner side of the heat emission outlet.

Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Abstract: A mobile terminal including a communication unit configured to communicate with at least one other terminal; a memory configured to store at least first and second operating systems including at least first and second modes, respectively; and a controller configured to execute the first and second operating systems, to simultaneously display first and second information screens on a display unit of the mobile terminal corresponding to the first and second modes, to receive a sharing signal requesting information from one of the first and second information screens be shared with the other of the first and second information screens, and to selectively share the requested information between the first and second information screens based on a predetermined criterion.

Abstract: A recombinant yeast cell having enhanced genetic manipulation efficiency, a method of preparing the recombinant yeast cell, and a method of preparing a biochemical by using the same.

Abstract: The present invention relates to a camera module including: a lens unit mounted with at least one or more lenses; an image sensor mounted with an image pickup device for converting a light converged through the lenses to an electric signal; a PCB (Printed Circuit Board) mounted with the image sensor; and a holder accommodated inside the lens unit for supporting the lens unit, wherein the lens unit is bonded and fixed at an inner surface of the holder, whereby the lens unit mounted with a plurality of lenses is bonded to a lateral surface of a holder to prevent generation of vertical tilting phenomenon at the lens unit caused by a conventional improper coating of epoxy, and particularly, the coating of epoxy on the lateral surface of the holder advantageously enhances adhesive power to increase a bonded area.

Abstract: A mobile terminal including a communication unit configured to communicate with at least one other terminal; a memory configured to store at least first and second operating systems including at least first and second modes, respectively; a controller configured to execute the first operating system, and to activate the first mode corresponding to the first operating system; and a display unit configured to display a first information screen corresponding to the activated first mode. Further, the first information screen includes first application information corresponding to the first mode and second application information corresponding to the second mode and an identifier identifying the first and second application information.

Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.

Abstract: The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.

Abstract: A mobile terminal supporting dual operating systems and an authentication method thereof. The mobile terminal includes a memory configured to store at least two different operating systems configured to act in at least two different modes, respectively, and a controller configured to perform an authentication procedure for authenticating that one mode can be switched to the other mode, and to display a type identifier only in one group identifier corresponding to a currently activated mode among the at least two different operating systems.